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DOI: 10.1002/gps.4948E D I TO R I A LRevision of assessment toolkits for improving the diagnosis of
Lewy body dementia: The DIAMOND Lewy studyAs part of the UK National Institute for Health Research DIAMOND
Lewy Programme (improving the DIagnosis And Management Of
Neurodegenerative Dementia of Lewy body type), we have reported in
this journal the development of two assessment toolkits to assist in
the recognition and diagnosis of Lewy body dementia.1 The “Assessment
Toolkit for Dementia with Lewy Bodies” is for use by clinicians in
memory and dementia services; the “Assessment Toolkit for Lewy Body
Dementia,” which facilitates an accurate diagnosis of either Parkinson's
disease (PD) dementia or dementia with Lewy bodies, is designed for
clinicians in movement disorder and geriatric medicine services.
The toolkits were developed to be easy to use by clinicians and to
align with consensus diagnostic criteria for these dementias. Since our
report appeared, the Fourth Consensus Report of the DLB consortium
on the diagnosis and management of DLB has been published.2 We
have therefore updated our toolkits to align them with the new
criteria and here summarise these changes. The link below takes you
to our original paper, where the development of these toolkits is
described (http://onlinelibrary.wiley.com/doi/10.1002/gps.4609/full)
and which is free to download. The revised toolkits are in the
Appendices to this Editorial.1 | CHANGES IN DLB DIAGNOSTIC
CRITERIA
Diagnosis of DLB according to previous 2005 criteria relied on the
identification of core features of DLB (fluctuating cognition, recurrent
complex visual hallucinations, and one or more spontaneous cardinal
features of parkinsonism) and suggestive features (REM sleep behaviour
disorder [RBD], neuroleptic sensitivity, and abnormal striatal dopaminergic
imaging). The two main changes in the Fourth Consensus Report are (1) to
upgrade RBD to become the fourth core clinical diagnostic feature and (2)
to restructure the criteria so suggestive features no longer appear, but are
replaced with “indicative biomarkers” and “supportive features.”2 | CORE FEATURES
RBD is a parasomnia in which movements and vocalisations occur
during REM sleep (dream reenactments) because of the absence of- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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cific validated question to identify RBD clinically. Where there is
doubt about RBD, polysomnography (PSG) should be considered.
The presence of two core clinical features is necessary to diagnose
probable DLB whilst one alone enables a possible DLB diagnosis.
Less prominent than the upgrading of RBD, but helpful and impor-
tant, is further clarification on parkinsonism. Whilst this has generally
been understood to exclude drug‐related and vascular parkinsonism,
it has been less clear which and how many motor features of PD are
required. PD requires the presence of bradykinesia (slowness of move-
ment and decrement in amplitude or speed) together with rest tremor
or rigidity or both.3 The Fourth Report specifies that for counting as a
core clinical feature for DLB, only one of these three features is suffi-
cient. Special care is necessary when assessing older people or those
with comorbidities, eg, osteoarthritis, or with advanced dementia
because these features may be misinterpreted in such situations. For
example, stiffness due to arthritis, or apraxia related to cognitive
impairment, may mimic bradykinesia. In such situations, a dopaminer-
gic scan should be considered. This leads to the other noticeable
change in these revised diagnostic criteria, namely, the emphasis on
biomarkers.3 | INDICATIVE BIOMARKERS
In the previous Third Consensus Report, low dopamine uptake in
the striatum on dopaminergic imaging was a suggestive feature of
DLB. In the Fourth Report, this is joined (under the new category
of indicative biomarkers) by abnormal (low uptake) cardiac MIBG
(123‐iodine‐MIBG myocardial scintigraphy) imaging and PSG evidence
of REM sleep without atonia. Abnormal MIBG imaging results from
the reduction in noradrenergic innervation of the myocardium in Lewy
body diseases4 whilst PSG demonstrating REM sleep without atonia is
the validated standard test for RBD.5 The presence of any one of
these in someone with dementia together with a core feature allows
the diagnosis of probable DLB. Abnormal biomarker evidence, even
more than one, in the absence of a core clinical feature only enables
a possible DLB diagnosis. Those familiar with the Third Report will- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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1294 EDITORIALnotice that of the three suggestive features in those criteria (abnormal
dopaminergic imaging, RBD, and severe neuroleptic sensitivity),
neuroleptic sensitivity has been “downgraded” to a supportive clinical
feature as “severe sensitivity to antipsychotic agents.” This may be
regarded as a good thing in that it reflects the greatly reduced use
of antipsychotics in people with dementia generally and in those likely
to have DLB in particular, with recent research reporting no study
subjects having this feature (eg, Walker et al6 and Donaghy et al7).
We have amended the toolkits to align with the new DLB criteria,
to maximise ease of use and utility. Clinicians experienced in the diag-
nosis of DLB may not need to routinely use these toolkits for all
patients, but our earlier study1 found clinicians greatly valued the
detail these toolkits provided about how to efficiently elicit the key
features of DLB in everyday clinical practice. This was especially true
for less experienced or trainee clinicians, and their routine use should
serve as a useful training experience to heighten awareness of DLB
symptoms and how to apply the new DLB diagnostic criteria.
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